A phase 1 first-in-human study of Abbv-383, a BCMA x CD3 bispecific T-cell-redirecting antibody, as monotherapy in patients with relapsed/refractory multiple myeloma Meeting Abstract
| Authors: | Voorhees, P. M.; D'Souza, A.; Weisel, K.; Hurd, D. D.; Teipel, R.; Chung, A.; Rodriguez, C.; Tuchman, S. A.; Korde, N.; Safah, H.; Bueno, O. F.; Pumford, N.; Rosenberg, T. S.; Pothacamury, R. K.; Ross, J. A.; Polepally, A. R.; Lee, S.; Jin, Z. Y.; Talati, C.; Vij, R.; Kumar, S. K. |
| Abstract Title: | A phase 1 first-in-human study of Abbv-383, a BCMA x CD3 bispecific T-cell-redirecting antibody, as monotherapy in patients with relapsed/refractory multiple myeloma |
| Meeting Title: | 64th Annual Meeting of the American Society of Hematology (ASH) |
| Journal Title: | Blood |
| Volume: | 140 |
| Issue: | Suppl. 1 |
| Meeting Dates: | 2022 Dec 10-13 |
| Meeting Location: | New Orleans, LA |
| ISSN: | 0006-4971 |
| Publisher: | American Society of Hematology |
| Date Published: | 2022-11-15 |
| Start Page: | 4401 |
| End Page: | 4404 |
| Language: | English |
| ACCESSION: | WOS:000893223204184 |
| DOI: | 10.1182/blood-2022-167008 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract -- Source: Wos |
